Baseline Participant Demographics | |
---|---|
Age (years) | 41.6 ± 10.0 |
BMI (kg/m2) | 27.9 ± 5.7 |
Sex (% Female) | 69% |
Race/ethnicity, non-Hispanic White (%) | 85% |
Age at diagnosis (years) | 34.5 ± 9.4 |
Time from symptom onset at enrollment (years) | 7.1 ± 4.6 |
Time since last relapse (years) | 4.5 ± 3.2 |
% Treated with natalizumab | 100% |
EDSS Score | 2.7 ± 1.9 |